Last reviewed · How we verify

NCT05751057: TITAN-MRI

The Role of Cardiovascular Magnetic Resonance in Patients With Non-ST- Elevation- Myocardial Infarction

Status unknown NA Last updated 2 March 2023
What this trial tests

NA trial testing Cardiovascular Magnetic Resonance in Non-ST Elevation Myocardial Infarction (NSTEMI) in 120 participants. Status unknown.

Timeline
14 December 2022
Primary endpoint
31 December 2023
31 December 2024

Quick facts

Lead sponsorCardiocentro Ticino
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposediagnostic
Enrollment120
Start date14 December 2022
Primary completion31 December 2023
Estimated completion31 December 2024
Sites1 location across Switzerland

Drugs / interventions tested

Conditions studied

Sponsor

Cardiocentro Ticino — full company profile →

Who can join

18 and older, any sex, with Non-ST Elevation Myocardial Infarction (NSTEMI). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this prospective study is to evaluate the role of cardiovascular magnetic resonance (CMR) in patients with suspected non-ST elevation myocardial infarction (NSTEMI). The main endpoint is the reclassification rate, defined as the number of patients in whom the information provided by pre-angiography CMR affects the revascularization strategy or the final diagnosis. Participants will undergo to CMR before invasive coronary angiography (ICA).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Cardiovascular Magnetic Resonance

Trials testing the same drug.

Other Cardiocentro Ticino trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05751057.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing